Search Results for "Pariet"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Pariet. Results 1 to 4 of 4 total matches.
See also: rabeprazole
Vonoprazan (Voquezna) for Nonerosive GERD
The Medical Letter on Drugs and Therapeutics • Oct 14, 2024 (Issue 1713)
― Vonoprazan blocks the final
step of acid secretion in the gastric parietal cell
by competitively blocking ...
The potassium-competitive acid blocker vonoprazan
(Voquezna – Phathom), which was approved earlier
for treatment of erosive esophagitis, has now been
approved by the FDA for relief of heartburn associated
with nonerosive gastroesophageal reflux disease
(GERD) in adults. Vonoprazan is also available
copackaged with amoxicillin (Voquezna Dual Pak) and
with amoxicillin and clarithromycin (Voquezna Triple
Pak) for treatment of Helicobacter pylori infection.
Med Lett Drugs Ther. 2024 Oct 14;66(1713):164-6 doi:10.58347/tml.2024.1713c | Show Introduction Hide Introduction
Comparison Table: H2-Receptor Antagonists and PPIs (online only)
The Medical Letter on Drugs and Therapeutics • Apr 04, 2022 (Issue 1647)
minutes. Pariet Pepcid Peptic ulcer disease Prevacid Prilosec Proton pump inhibitors Protonix Rabeprazole ...
View the Comparison Table: H2-Receptor Antagonists and PPIs
Vonoprazan (Voquezna) for Erosive Esophagitis
The Medical Letter on Drugs and Therapeutics • Dec 25, 2023 (Issue 1692)
secretion in the gastric parietal cell
by competitively blocking potassium binding to
hydrogen-potassium ...
The FDA has approved vonoprazan (Voquezna –
Phathom), a potassium-competitive acid blocker, for
healing and maintenance of healing of all grades of
erosive esophagitis and relief of associated heartburn in adults. Vonoprazan is also available copackaged
with amoxicillin (Voquezna Dual Pak) and with
amoxicillin and clarithromycin (Voquezna Triple Pak)
for treatment of Helicobacter pylori infection in adults.
Med Lett Drugs Ther. 2023 Dec 25;65(1692):203-5 doi:10.58347/tml.2023.1692b | Show Introduction Hide Introduction
Drugs for GERD and Peptic Ulcer Disease
The Medical Letter on Drugs and Therapeutics • Apr 04, 2022 (Issue 1647)
of histamine at H2 receptors on parietal
cells, decreasing basal acid secretion and, to a
much lesser extent ...
Gastroesophageal reflux disease (GERD) is the most
common GI condition encountered in the outpatient
setting; it affects about 20% of people in the US.